ASCO Annual Meeting | Conference

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC

May 31st 2020

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma

May 31st 2020

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment

May 31st 2020

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

May 31st 2020

Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC

May 31st 2020

In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC

May 31st 2020

Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 31st 2020

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 31st 2020

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC

May 31st 2020

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

Cabozantinib/Atezolizumab Combo Shows Promise in Previously Treated Urothelial Carcinoma

May 31st 2020

The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

May 31st 2020

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

May 31st 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

May 31st 2020

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC

May 31st 2020

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

May 30th 2020

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

May 30th 2020

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma

May 30th 2020

An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.

Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC

May 30th 2020

The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

May 30th 2020

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.